U.S. markets open in 6 hours 48 minutes
  • S&P Futures

    4,383.25
    -38.50 (-0.87%)
     
  • Dow Futures

    34,077.00
    -385.00 (-1.12%)
     
  • Nasdaq Futures

    15,220.00
    -106.00 (-0.69%)
     
  • Russell 2000 Futures

    2,200.10
    -28.20 (-1.27%)
     
  • Crude Oil

    71.36
    -0.61 (-0.85%)
     
  • Gold

    1,751.40
    0.00 (0.00%)
     
  • Silver

    22.40
    +0.06 (+0.28%)
     
  • EUR/USD

    1.1716
    -0.0015 (-0.13%)
     
  • 10-Yr Bond

    1.3700
    0.0000 (0.00%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3697
    -0.0041 (-0.30%)
     
  • USD/JPY

    109.8300
    -0.0650 (-0.06%)
     
  • BTC-USD

    45,545.61
    -2,488.59 (-5.18%)
     
  • CMC Crypto 200

    1,135.99
    -89.54 (-7.31%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Inovio's DNA COVID-19 Vaccine Candidate Triggers Immune Response In Pivotal Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Inovio Pharmaceuticals Inc (NASDAQ: INO) has announced positive data from the Phase 2 segment of its Phase 2/3 INNOVATE trial in the U.S., evaluating INO-4800, its DNA vaccine candidate for COVID-19.

  • The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older.

  • Preliminary results show that INO-4800 was generally safe, well-tolerated, and immunogenic in all studied age groups in a larger population.

  • Safety endpoints included systemic and local administration site reactions through 8 weeks post-dose one (or 4 weeks post-dose 2).

  • Immunology endpoints included antigen-specific binding antibody titers, neutralization titers, and antigen-specific interferon-gamma (IFN-γ) cellular immune responses after two doses of the vaccine.

  • Vaccine administration was generally safe and well-tolerated. The majority of adverse events were mild and moderate in severity and did not appear to increase in frequency with the second dose.

  • The geometric mean fold rise (GMFR) of binding and neutralizing antibody levels were statistically significantly greater in the 2.0 mg dose group versus the 1.0 mg dose group.

  • The T cell immune responses measured by the ELISpot assay were also higher in the 2.0 mg dose group compared to the 1.0 mg dose group.

  • "The expanded data set enabled a clear dose selection to be made with 2.0 mg as the dose for the global Phase 3 efficacy trial," said Dr. Laurent M. Humeau, INO's Chief Scientific Officer.

  • Price Action: INO shares are down 2.04% at $6.70 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.